Continuing treatment for itching in primary biliary cholangitis
Part of Digestive system, Skin clinical trials.
This study continues to test an experimental medicine (linerixibat) for itching caused by primary biliary cholangitis (PBC). It's for people who have already been in a prior study of this medicine and may help keep itching under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary biliary cholangitis (PBC) and have had itching related to it.
- You were previously enrolled in a qualifying study of the medicine linerixibat (such as GLIMMER or GLISTEN) and have completed the main treatment period.
- You are not pregnant, not breastfeeding, and if you can have children, you agree to use birth control during the study and for at least 4 weeks after the last dose.
- You are willing to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called linerixibat for people with primary biliary cholangitis (PBC) who have severe itching that hasn't responded to other treatments and who are at risk of serious complications from the itching. It aims to help reduce this itching and improve quality of life.
This trial tests an experimental drug called TH104 to see if it can reduce itching in people with primary biliary cholangitis. The study will help find out if TH104 is safe and effective for this symptom.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This study looks at itching caused by drug-induced liver injury. Researchers want to understand who gets itchy and how bad it is, which could help improve care for people with this condition.
This study tests a light-based therapy (called photobiomodulation) to see if it can reduce itch. The treatment uses a special light on the skin, which may help calm the nerves or cells that cause itching. You'll have one side of your body treated and the other side not, so the researchers can compare the effects.
This trial tests whether upadacitinib, a drug that calms the immune system, can help people with autoimmune liver disease and severe itching from atopic dermatitis (eczema). It aims to reduce itching and improve liver health.
Hear when a new Pruritus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.